| __timestamp | Iovance Biotherapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 60987000 |
| Thursday, January 1, 2015 | 999000 | 125542000 |
| Friday, January 1, 2016 | 978000 | 210460000 |
| Sunday, January 1, 2017 | 952000 | 275119000 |
| Monday, January 1, 2018 | 956000 | 409539000 |
| Tuesday, January 1, 2019 | 8122999 | 547758000 |
| Wednesday, January 1, 2020 | 8712000 | 736300000 |
| Friday, January 1, 2021 | 13980000 | 904200000 |
| Saturday, January 1, 2022 | 21135000 | 1080300000 |
| Sunday, January 1, 2023 | 10755000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Vertex Pharmaceuticals Incorporated and Iovance Biotherapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Vertex Pharmaceuticals, a leader in the industry, has consistently managed its cost of revenue, peaking at approximately $1.26 billion in 2023, a staggering 20-fold increase from 2014. This reflects their strategic investments and operational efficiency. In contrast, Iovance Biotherapeutics, a smaller player, saw its cost of revenue rise to $21 million in 2022, a significant increase from its 2014 figure. This growth, while substantial, highlights the challenges smaller firms face in scaling operations efficiently. As the biotech sector continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders aiming to navigate this complex market.
Cost Insights: Breaking Down Johnson & Johnson and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Trends: Pfizer Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Viatris Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Grifols, S.A.
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
MorphoSys AG vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.